In all 55 patients who provided a blood specimen (Table 5), the final model for numbness/tingling included worse baseline neuropathy (28%), stage I cancer (17%), worse fatigue/anxiety/depression (15%), higher pro-inflammatory IFN-γ (12%), the use of diabetes medications (11%), black race (8%), higher pro-inflammatory IL-1β (6%), lower anti-inflammatory IL-10 (6%) and higher pro-inflammatory IL-8 (1%). The gene discussed is IL10; the disease is cancer.